Skip to content
2000
Volume 12, Issue 1
  • ISSN: 1573-4080
  • E-ISSN: 1875-6662

Abstract

NO is a key signaling molecule that has a wide range of biological functions including vasodilation and neurotransmission, and is implicated in several pathological conditions. Therefore, modulation of NO is a desired step in curbing the NO-associated disease processes. Targetting NOS proteins and inhibiting their activity to reduce NO production is a major approach since the inception of NOS inhibitor research. Although a series of NOS inhibitors have been developed, synthesized and practiced in experimental biology, no NOS inhibitor has been approved as yet a drug for therapeutic uses. The present review elaborates the scope of the clinical uses of NOS inhibitors and the inherent limitations of the process that makes the approach less successful so far in clinic.

Loading

Article metrics loading...

/content/journals/cei/10.2174/1573408012666151126185922
2016-04-01
2025-06-18
Loading full text...

Full text loading...

/content/journals/cei/10.2174/1573408012666151126185922
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test